Adverse effects of testosterone replacement therapy: An update on the evidence and controversy

Therapeutic Advances in Drug Safety

Volumn 5, Issue 5, 2014, Pages 190-200

  Grech, Anthony ^a   Breck, John ^a   Heidelbaugh, Joel ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

adverse effects; cardiovascular risk; mortality; prostate specific antigen; testosterone

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADVERSE DRUG REACTION; ANDROGEN DEFICIENCY; ANDROGEN THERAPY; CANCER RISK; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; ERYTHROCYTOSIS; HUMAN; ISCHEMIC HEART DISEASE; LOWER URINARY TRACT SYMPTOM; MEDICAL SUBJECT HEADINGS; MEDLINE; PANCREAS CANCER; REVIEW; SLEEP DISORDERED BREATHING; TESTOSTERONE BLOOD LEVEL;

EID: 84907212881     PISSN: 20420986     EISSN: 20420994     Source Type: Journal    
DOI: 10.1177/2042098614548680     Document Type: Review

References (46)

1. Andriole G. Crawford E. Grubb III R. Buys S. Chia D. Church T. (2012) Prostate cancer screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst 104: 125–132.
2. Araujo A. Esche G. Kupelian V. O–Donnell A. Travison T. Williams R. (2007) Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92: 4241–4247.
3. Baillargeon J. Urban R. Ottenbacher K. Pierson K. Goodwin J. (2013) Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 173: 1465–1466.
4. Barrett-Connor E. Dam T. Stone K. Harrison S. Redline S. Orwoll E. (2008) The association of testosterone levels with overall sleep quality, sleep architecture, and sleep-disordered breathing. J Clin Endocrinol Metab 93: 2602–2609.
5. Basaria S. Coviello A. Travison T. Storer T. Farwell W. Jette A. (2010) Adverse Events Associated with Testosterone Administration. N Engl J Med 363: 109–122.
6. Basaria S. Davda M. Travison T. Ulloor J. Singh R. Bhasin S. (2013) Risk factors associated with cardiovascular events during testosterone administration in older men with mobility limitation. J Gerontol A Biol Sci Med Sci 68: 153–160.
7. Bercea R. Patacchioli F. Ghiciuc C. Cojocaru E. Mihaescu T. (2013) Serum testosterone and depressive symptoms in severe OSA patients. Andrologia 45: 345–350.
8. Bhasin S. Cunningham G. Hayes F. Matsumoto A. Snyder P. Swerdloff R. (2010) Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 95: 2536–2559.
9. Bhattacharya R. Khera M. Blick G. Kushner H. Miner M. (2012) Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS). Clinical Interventions in Aging 7: 321–330.
10. Calof O. Singh A. Lee M. Kenny A. Urban R. Tenover J. (2005) Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol 60: 1451–1457.
11. Corona G. Rastrelli G. Vignozzi L. Mannucci E. Maggi M. (2011) Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract Res Clin Endocrinol Metab 25: 337–353.
12. Corona G. Vignozzi L. Sforza A. Maggi M. (2013) Risks and benefits of late onset hypogonadism treatment: an expert opinion. World J Mens Health 31: 103–125.
13. Coviello A. Kaplan B. Lakshman K. Chen T. Singh A. Bhasin S. (2008) Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab 93: 914–919.
14. Coward R. Simhan J. Carson C. (2008) Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy. BJU Int 103: 1179–1183.
15. Fernandez-Balsells M. Murad M. Lane M. Lampropulos J. Albuquerque F. Mullan R. (2010) Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95: 2560–2575.
16. Finkle W. Greenland S. Ridgeway G. Adams J. Frasco M. Cook M. (2014) Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLOS One 9: 1–7.
17. Hall S. Araujo A. Esche G. Williams R. Clark R. Travison T. (2008) Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey. Arch Intern Med 168: 1070–1076.
18. Holmegard H. Nordestgaard B. Schnohr P. Tybjaerg-Hansen A. Benn M. (2014) Endogenous sex hormones and risk of venous thromboembolism in women and men. J Thromb Haemost 12: 297–305.
19. Hoyos C. Killick R. Yee B. Grunstein R. Liu P. (2012a) Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 7: 599–607.
20. Hoyos C. Yee B. Phillips C. Machan E. Grunstein R. Liu P. (2012b) Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 167: 531–541.
21. Jackson G. Montorsi P. Adams M. Anis T. El-Sakka A. Miner M. (2010) Cardiovascular aspects of sexual medicine. J Sex Med 7: 1608–1626.
22. Kaplan A. Hu J. (2013) Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes. Urology 82: 321–326.
23. Killick R. Wang D. Hoyos C. Yee B. Grunstein R. Liu P. (2013) The effects of testosterone on ventilatory responses in men with obstructive sleep apnea: a randomised, placebo-controlled trial. J Sleep Res 22: 331–336.
24. Maggio M. Snyder P. Ceda G. Milaneschi Y. Luci M. Cattabiani C. (2013) Is the haematopoietic effect of testosterone mediated by erythropoietin? The results of a clinical trial in older men. Andrology 1: 24–28.
25. Mohr B. Guay A. O–Donnell A. McKinlay J. (2005) Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts Male Ageing Study. Clin Endocrinol 62: 64–73.
26. Morgentaler A. (2011) Testosterone and prostate cancer: what are the risks for middle-aged men? Urol Clin N Am 38: 119–124.
27. Morgentaler A. Traish A. (2008) Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth. Eur Urol 55: 310–321.
28. Mulligan T. Frick M. Zuraw Q. Stemhagen A. McWhirter C. (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60: 762–769.
29. Muraleedharan V. Marsh H. Kapoor D. Channer K. Hones T. (2013) Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 169: 725–733.
30. Page S. Amory J. Bowman F. Anawalt B. Matsumoto A. Bremner W. (2005) Exogenous testosterone (T) alone or with finasteride increases physical performance, grip strength, and lean body mass in men with low serum T. J Clin Endocrinol Metab 90: 1502–1510.
31. Page S. Hirano L. Gilchriest J. Dighe M. Amory J. Marck B. (2011) Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. J Urol 186: 191–197.
32. Pearl J. Berhanu D. Francois N. Masson P. Zargaroff S. Cashy J. (2013) Testosterone supplementation does not worsen lower urinary tract symptoms. J Urol 190: 1828–1833.
33. Raynaud J. Gardette J. Rollet J. Legros J. (2013) Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment. BJU Int 111: 880–890.
34. Shabsigh R. (2003) Hypogonadism and erectile dysfunction: the role for testosterone therapy. Int J Impot Res 15(Suppl. 4): S9–S13.
35. Shigehara K. Sugimoto K. Konaka H. Iijima M. Fukushima M. Maeda Y. (2011) Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. The Aging Male 14: 53–58.
36. Shores M. Smith N. Forsberg C. Anawalt B. Matsumoto A. (2012) Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 97: 2050–2058.
37. Schroder F. Hugosson J. Roobol M. Tammela T. Ciatto S. Nelen V. (2012) Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366: 981–990.
38. Svartberg J. Braekkan S. Laughlin G. Hansen J. (2009) Endogenous sex hormone levels in men are not associated with risk of venous thromboembolism: the Tromso study. Eur J Endocrinol 160: 833–838.
39. Tan W. Low W. Ng C. Tan W. Tong S. Ho C. (2013) Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: a randomized controlled study. BJU Int 111: 1130–1140.
40. Traish A. Guay A. Morgentaler A. (2014) Death by testosterone? We think not! J Sex Med 11: 624–629.
41. Traish A. Haider A. Doros G. Saad F. (2013) Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 68: 314–329.
42. Vigen R. O–Donnell C. Baron A. Grunwald G. Maddox T. Bradley S. (2013) Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 310: 1829–1836.
43. Wu F. Tajar A. Pye S. Silman A. Finn J. O–Neill T. (2008) Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 93: 2737–2745.
44. Xu L. Freeman G. Cowling B. Schooling C. (2013) Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 11: 108.
45. Yassin D. El Douaihy Y. Yassin A. Kashanian J. Shabsigh R. Hammerer P. (2014) Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World J Urol 32: 1049–1054.
46. Zitzmann M. Mattern A. Hanisch J. Gooren L. Jones H. Maggi M. (2013) IPASS: A study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 10: 579–588.